MKI67 and chronic myelogenous leukemia, BCR-ABL1 positive: We next hypothesised that SHIN1 primes a fraction of primitive CML cells out of quiescence, thus we treated CML CD34+ cells (n = 4) with imatinib, SHIN1 or a combination of both for 48 h and stained them with the proliferation marker Ki67, and the DNA stain DAPI (Supplementary Fig. 8c).